Avalo Therapeutics (AVTX) Capital Expenditures (2016 - 2023)

Avalo Therapeutics has reported Capital Expenditures for 8 years, with the latest figure at $158000.0 in Q1 2023.

• For the quarter ending Q1 2023, Capital Expenditures changed N/A year-over-year to $158000.0; the trailing twelve-month figure through Dec 2023 stood at $158000.0 (changed N/A YoY), and the FY2023 full-year result was $158000.0, changed N/A from the prior year.
• Capital Expenditures for Q1 2023 stood at $158000.0, up from -$95000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $165969.0 in Q1 2019, with the low at -$95000.0 in Q4 2022.
• Historically, Capital Expenditures has averaged $49667.8 across 5 years, with a median of $47500.0 in 2022.
• Annual changes were most pronounced in 2019 — Capital Expenditures jumped 1256.15% — and 2022, when it tumbled 963.64%.
• Avalo Therapeutics' Capital Expenditures stood at $2.0 in 2019, then soared by 3149900.0% to $63000.0 in 2020, then tumbled by 82.54% to $11000.0 in 2021, then plunged by 963.64% to -$95000.0 in 2022, then jumped by 266.32% to $158000.0 in 2023.
• The last three Capital Expenditures figures came in at $158000.0 (Q1 2023), -$95000.0 (Q4 2022), and $39000.0 (Q3 2022), per Business Quant data.